Immunosuppressive therapy in elderly patients with neuromyelitis optica spectrum disorder: a retrospective multicentre study

医学 硫唑嘌呤 中止 不利影响 视神经脊髓炎 美罗华 内科学 回顾性队列研究 入射(几何) 儿科 疾病 免疫学 抗体 淋巴瘤 光学 物理
作者
Ki Hoon Kim,Yeon Hak Chung,Ju‐Hong Min,Hee Jo Han,Seung Woo Kim,Ha Young Shin,Young Nam Kwon,Sung‐Min Kim,Young‐Min Lim,Hyunjin Kim,Eun‐Jae Lee,Seong Ho Jeong,Jae‐Won Hyun,Su‐Hyun Kim,Ho Jin Kim
出处
期刊:Journal of Neurology, Neurosurgery, and Psychiatry [BMJ]
卷期号:95 (12): 1168-1175 被引量:2
标识
DOI:10.1136/jnnp-2024-333644
摘要

Background The risk–benefit relationship of immunosuppressive therapies (ISTs) for elderly patients with neuromyelitis optica spectrum disorder (NMOSD) is not well established. This study aimed to investigate the safety and efficacy of IST in elderly patients with NMOSD. Methods This retrospective study analysed IST efficacy and safety in 101 patients with aquaporin-4 antibody-positive NMOSD aged over 65 years, treated for at least 6 months at five Korean referral centres, focusing on relapse rates, infection events and discontinuation due to adverse outcomes. Results The mean age at disease onset was 59.8 years, and female-to-male ratio was 4:1. Concomitant comorbidities at NMOSD diagnosis were found in 87 patients (86%). The median Expanded Disability Status Scale score at the initiation of IST was 3.5. The administered ISTs included azathioprine (n=61, 60%), mycophenolate mofetil (MMF) (n=48, 48%) and rituximab (n=41, 41%). Over a median of 5.8 years of IST, 58% of patients were relapse-free. The median annualised relapse rate decreased from 0.76 to 0 (p<0.001), and 81% experienced improved or stabilised disability. Patients treated with rituximab had a higher relapse-free rate than those treated with azathioprine or MMF (p=0.022). During IST, 21 patients experienced 25 severe infection events (SIEs) over the age of 65 years, and 3 died from pneumonia. 14 patients (14%) experienced 17 adverse events that led to switching or discontinuation of IST. When comparing the incidence rates of SIEs and adverse events, no differences were observed among patients receiving azathioprine, MMF and rituximab. Conclusion In elderly patients with NMOSD, IST offers potential benefits in reducing relapse rates alongside a tolerable risk of adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
虚幻谷波完成签到,获得积分10
3秒前
ruochenzu发布了新的文献求助10
6秒前
小马甲应助搞怪梦寒采纳,获得10
8秒前
firewood完成签到 ,获得积分10
9秒前
天天快乐应助普鲁卡因采纳,获得10
11秒前
orixero应助NXK采纳,获得10
11秒前
bjr完成签到 ,获得积分10
13秒前
研友_LwlAgn完成签到,获得积分10
17秒前
陈昊完成签到,获得积分10
25秒前
26秒前
tian发布了新的文献求助10
28秒前
31秒前
31秒前
龙舞星完成签到,获得积分10
32秒前
33秒前
王涉发布了新的文献求助10
35秒前
普鲁卡因发布了新的文献求助10
36秒前
量子星尘发布了新的文献求助10
38秒前
柚子完成签到,获得积分10
42秒前
43秒前
马儿饿了要吃草完成签到,获得积分10
43秒前
45秒前
sudor123456完成签到,获得积分10
50秒前
NXK发布了新的文献求助10
50秒前
打打应助普鲁卡因采纳,获得10
53秒前
55秒前
lii完成签到,获得积分10
55秒前
jiaolulu发布了新的文献求助10
1分钟前
个性惜蕊完成签到,获得积分10
1分钟前
1分钟前
轩辕书白完成签到,获得积分10
1分钟前
qinzhikai完成签到,获得积分10
1分钟前
天真的冬瓜完成签到,获得积分10
1分钟前
小溜溜完成签到 ,获得积分10
1分钟前
普鲁卡因发布了新的文献求助10
1分钟前
tian发布了新的文献求助10
1分钟前
桃花源的瓶起子完成签到 ,获得积分10
1分钟前
平凡世界完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022